摘要
恶性心包积液(MPCE)是晚期恶性肿瘤常见的并发症之一,严重时可危及患者生命。目前关于MPCE的治疗以心包腔穿刺引流联合心包腔药物灌注为主。心包腔灌注治疗药物种类繁多,既包括传统的细胞毒性药物,也包括抗血管生成靶向药物、生物制剂、中成药注射液等。其中,抗血管生成靶向药物贝伐珠单抗、重组人血管内皮抑制素和生物制剂肿瘤坏死因子等治疗MPCE疗效显著,而免疫检查点抑制剂、中成药注射液以及其他疗法在MPCE中也具有一定治疗作用。未来深入研究这些药物在MPCE中的作用机制,可以为疾病的治疗提供新思路。
Malignant pericardial effusion(MPCE)is one of the common complications of advanced malignant tumors,which may threaten the lives of the patients in severe cases.At present,pericardial puncture and effusion drainage combined with pericardial perfusion remain the primary option for MPCE.There is a large number of pericardial perfusion agents,including traditional cytotoxic drugs,antivascular-targeted agents,biological agents,Chinese patent medicine injection,etc.Among them,the anti-angiogenic agents such as bevacizumab,endostar,and the biological agent tumor necrosis factor have significant efficacy in treating MPCE,while immune checkpoint inhibitors,Chinese patent medicine injections,and other treatment measures also have some therapeutic effects on MPCE.With the deeper exploration of the mechanism of action of these drug in MPCE in the future,new ideas for the treatment of diseases can be provided.
作者
彭飞
郑琪
白杰
呼延卓雅
李索妮
廖子君
PENG Fei;ZHENG Qi;BAI Jie;HUYAN Zhuoya;LI Suoni;LIAO Zijun(Department of Postgraduate,Xi′an Medical University,Xi′an 710068,China;Department One of Medical Oncology,Affiliated Shaanxi Provincial Tumor Hospital,College of Medicine,Xi′an Jiaotong University,Xi′an 710061,China)
出处
《医学综述》
CAS
2023年第6期1156-1162,共7页
Medical Recapitulate
基金
陕西省重点研发计划项目(2019SF-217)。
关键词
恶性心包积液
心包腔灌注治疗
抗血管靶向药物
Malignant pericardial effusion
Pericardial perfusion therapy
Antivascular-targeted drugs
